|
Volumn 10, Issue 4, 2009, Pages 233-253
|
Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland
|
Author keywords
Antiretroviral; Cost effectiveness; ICER; Raltegravir; Switzerland
|
Indexed keywords
PLACEBO;
PROTEINASE INHIBITOR;
RALTEGRAVIR;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
VIRUS RNA;
ADD ON THERAPY;
ADULT;
ANTIVIRAL RESISTANCE;
ANTIVIRAL THERAPY;
ARTICLE;
CD4 LYMPHOCYTE COUNT;
COHORT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
DRUG EFFECT;
DRUG UTILIZATION;
FEMALE;
HEALTH STATUS;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION;
HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT;
LIFE EXPECTANCY;
MAJOR CLINICAL STUDY;
MALE;
OPPORTUNISTIC INFECTION;
PRIORITY JOURNAL;
QUALITY ADJUSTED LIFE YEAR;
QUALITY OF LIFE;
SENSITIVITY ANALYSIS;
SWITZERLAND;
TREATMENT DURATION;
VIRUS LOAD;
AIDS-RELATED OPPORTUNISTIC INFECTIONS;
CD4 LYMPHOCYTE COUNT;
COHORT STUDIES;
COMPUTER SIMULATION;
COST-BENEFIT ANALYSIS;
FEMALE;
HIV INFECTIONS;
HIV INTEGRASE INHIBITORS;
HIV-1;
HUMANS;
MALE;
MARKOV CHAINS;
MIDDLE AGED;
MODELS, ECONOMIC;
PYRROLIDINONES;
QUALITY-ADJUSTED LIFE YEARS;
RNA, VIRAL;
SWITZERLAND;
|
EID: 70349141758
PISSN: 15284336
EISSN: None
Source Type: Journal
DOI: 10.1310/hct1004-233 Document Type: Article |
Times cited : (13)
|
References (6)
|